Tirzepatide vs. Semaglutide: What They Actually Cost

Tirzepatide and semaglutide are both GLP-1–based medications used for weight management and type 2 diabetes, and they're often mentioned in the same breath — which makes their price difference feel more confusing than it needs to be. The honest answer is that cost depends heavily on which product you're comparing (brand name vs. a generic-sounding compounded version), which condition it's prescribed for, and whether insurance is involved at all. Here's how the numbers actually break down.

Brand-Name Pricing, Compared

Tirzepatide is sold under two brand names: Zepbound (approved for weight management) and Mounjaro (approved for type 2 diabetes, sometimes prescribed off-label for weight loss). Semaglutide is sold as Wegovy (weight management) and Ozempic (diabetes, also sometimes prescribed off-label for weight loss).

Manufacturer list prices for all four products run well over $1,000 a month without any discount. But both Eli Lilly and Novo Nordisk offer direct-to-consumer self-pay programs that bring the real cost down substantially for patients paying out of pocket. As of late 2025 and into 2026, Lilly's self-pay program prices Zepbound single-dose vials at roughly $299 a month for the starting 2.5mg dose, $399 for 5mg, and $449 for 7.5mg and higher maintenance doses. Novo Nordisk's NovoCare pharmacy prices Wegovy between roughly $149 and $349 a month depending on dose and formulation (oral tablet vs. injectable pen), with a lower introductory rate for new patients in the first two months.

Mounjaro and Ozempic — the diabetes-indicated versions of the same molecules, sometimes prescribed off-label for weight loss — are priced differently and generally don't have the same discounted self-pay vial option that Zepbound does. If a clinician is considering one of these for weight management specifically, it's worth asking directly about current self-pay pricing, since manufacturer programs change fairly often.

Why the Price Gap Isn't the Whole Story

Comparing sticker prices alone misses an important variable: the two drugs don't produce the same average results. Semaglutide is a GLP-1 receptor agonist alone, while tirzepatide is a dual GIP/GLP-1 receptor co-agonist — it acts on two hormone pathways instead of one, which is the mechanistic reason it tends to outperform semaglutide on average.

That difference shows up directly in head-to-head data. A randomized trial published in the New England Journal of Medicine in 2025 (SURMOUNT-5) compared tirzepatide and semaglutide directly in adults without diabetes, at maximum tolerated doses, over 72 weeks. Tirzepatide produced an average 20.2% reduction in body weight, compared with 13.7% for semaglutide — a meaningful gap. That doesn't automatically make tirzepatide the better value for everyone; individual response, side-effect tolerance, and dosing all vary. But it's worth factoring "cost per pound lost," not just monthly price, into the comparison.

What About Compounded Versions?

During the 2023–2024 shortage of both drugs, compounding pharmacies were legally permitted to prepare custom versions of tirzepatide and semaglutide, and they were often advertised well below brand-name prices. That's part of why "compounded" and "cheap GLP-1" became linked in a lot of people's minds.

That landscape has changed. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Once a drug is off the shortage list, the legal basis for compounding pharmacies to prepare large-scale, "essentially a copy" versions of it goes away. As of 2026, licensed 503A pharmacies can still compound either drug for an individual patient, but only when a prescriber documents a genuine clinical reason — a documented allergy to an inactive ingredient, or a need for a dosage form that isn't commercially available — not simply because it's cheaper. Large-scale 503B outsourcing facilities generally can't compound either drug at all under current rules, and the FDA has proposed making that restriction permanent. If you see a compounded price that looks too good to be true relative to what's legally available today, it's worth asking exactly how that pharmacy is sourcing and justifying the prescription.

Insurance and Other Ways to Lower the Cost

Insurance coverage is the other major variable, and it depends heavily on which condition the drug is prescribed for. Coverage for type 2 diabetes (Ozempic, Mounjaro) tends to be far more reliable than coverage for weight management alone (Wegovy, Zepbound), where a large share of commercial plans either don't cover the drug or require prior authorization. When a plan does cover it, out-of-pocket copays with a manufacturer savings card commonly land somewhere between $25 and $150 a month.

Medicare has historically been barred by statute from covering obesity medications specifically, but a temporary CMS pilot program beginning July 1, 2026 will cover Wegovy, Zepbound, and at least one newer GLP-1 drug at a flat $50 monthly copay for beneficiaries who meet certain BMI and health-risk criteria, subject to prior authorization. Not every Medicare Part D plan is required to participate, so it's worth confirming directly with your plan.

The Bottom Line

Neither drug has a single, fixed price — both vary substantially by brand, dose, pharmacy, and insurance status, and the gap between "list price" and "what you'd actually pay" is often enormous. The more useful comparison isn't which drug is cheaper on paper, but which one, at a price and dosing schedule you can sustain, is likely to get you the result you're looking for. That's a conversation worth having directly with a licensed clinician who can weigh your history, your goals, and your coverage together, rather than choosing based on an advertised price alone.